Mangoceuticals (MGRX): supplier map and what it means for investors

Mangoceuticals operates a telemedicine-driven retail model that monetizes through direct-to-consumer prescription fulfillment, licensed product lines, intellectual‑property transactions and bespoke service agreements, while supplementing cash through occasional equity raises. The company’s value proposition is built on branded telehealth channels (MangoRx / PeachesRx), outsourced pharmacy fulfillment, IP acquisitions, and newer experiments in digital-asset treasury management and animal-health R&D. For investors evaluating supplier relationships, the important takeaway is that the business combines high operational leverage with concentrated third‑party dependencies and episodic large capital commitments. Learn more at https://nullexposure.com/.

How Mangoceuticals structures its supplier footprint — an investor view

Mangoceuticals runs a hybrid operating model: it is a retail/telemedicine platform that selectively licenses IP and purchases patents, while relying on external service providers for pharmacy fulfillment, clinical staffing and specialty manufacturing. Company filings show a mix of long‑term master services agreements and shorter, transactional contracts, and public filings document both routine vendor spend and a very large patent acquisition. These dynamics create three investment‑relevant signals:

• Contracting posture: The company uses long‑dated master services agreements for core functions (pharmacy fulfillment and certain consulting relationships) alongside discrete licensing and patent purchases for product expansion; the 10‑K enumerates multi‑year terms and automatic renewals for key contracts.
• Concentration & criticality: A small number of vendors provide mission‑critical capabilities (mail‑service pharmacy, telemedicine physicians and packaging/compounding). Loss of an exclusive pharmacy services partner would materially disrupt fulfillment.
• Maturity & optionality: Relationships span incubation (R&D and animal‑health partnerships), product commercialization (licensed skincare and TRT programs) and experimental treasury management (a Solana‑focused DAT). That mix implies high operational optionality but also elevated execution risk.

If you want a consolidated supplier intelligence briefing on Mangoceuticals, start here: https://nullexposure.com/.

Relationship map — every supplier and partner referenced in public results

Below are the suppliers, advisors and partners that show up in Mangoceuticals’ public record and press coverage, with a plain‑English summary and the supporting source.

Epiq Scripts, LLC

Epiq Scripts is Mangoceuticals’ exclusive mail‑service pharmacy and compounding/fulfillment provider under a Master Services Agreement that supports online fulfillment, specialty compounding, packaging, shipping, dispensing and distribution for products sold on the company’s platform; the 10‑K also shows an upfront technology/setup payment. (Source: Mangoceuticals 2024 Form 10‑K / Master Services Agreement, FY2024; QZ summary of 10‑Q.)

Propre Energie Inc

Propre is the counterparty to a Master Distribution Agreement dated January 30, 2025 under which Mangoceuticals will license certain IP and patent rights for plant‑based dermatology formulations marketed as Dermytol; the MDA includes equity consideration and a revenue share structure. (Source: Mangoceuticals 2024 Form 10‑K / MDA, FY2024–FY2025.)

Lucosky Brookman LLP

Lucosky Brookman acted as legal counsel to Mangoceuticals in the company’s December 2025 registered direct and private placement financing that closed for $2.5 million. (Source: GlobeNewswire press release, December 19, 2025.)

Aegis Capital Corp.

Aegis served as the exclusive placement agent on Mangoceuticals’ late‑2025 equity offerings that provided incremental working capital and included share and warrant financings. (Source: GlobeNewswire and related financial press coverage, December 2025; QuiverQuant recap.)

Novo Nordisk (NVO)

Mangoceuticals announced programs offering customers access to Novo Nordisk’s Wegovy® through established pharmacy channels, but subsequent communications clarified Mangoceuticals has no direct contractual relationship with Novo Nordisk and relies on approved third‑party pharmacy channels to provide branded GLP‑1 medicines. (Source: GlobeNewswire clarification, November 14, 2025; Pharmaceutical‑Technology reporting.)

Eli Lilly (LLY)

Mangoceuticals publicized direct access to Eli Lilly’s Zepbound® via its MangoRx/PeachesRx channels and indicated fulfillment pathways using LillyDirect Self‑Pay Pharmacy Solutions, but major press reported Eli Lilly distanced itself from direct partnership claims. (Source: GlobeNewswire release, November 13–14, 2025; Pharmaceutical‑Technology reporting.)

Cube / Cube Group

Cube Group (branded in press as Cube) was engaged under a Master Services Agreement to manage a Solana‑focused digital‑asset treasury strategy (Mango DAT), with Cube appointed as asset manager for custody, execution and strategy on an up‑to‑$100 million mandate. (Source: GlobeNewswire and related press, December 19, 2025.)

IntraMont Technologies / Intramont Technologies, Inc.

Mangoceuticals executed a Patent Purchase Agreement that references Intramont (Intramont/ IntraMont) and has public R&D collaboration notes: Intramont is cited in filings and press as a counterparty to IP purchases and technical reports supporting MGX‑0024 antiviral work. (Source: Mangoceuticals 10‑K / IP Purchase Agreement; QuiverQuant research notes, late‑2025/early‑2026.)

Vipragen Biosciences

Vipragen conducted a controlled challenge study under BSL‑3 conditions that evaluated MGX‑0024 for avian H5N1 and related poultry respiratory pathogens, supporting Mangoceuticals’ antiviral program. (Source: QuiverQuant summary of MGX‑0024 results, FY2026.)

Solice International

Solice partnered with Mangoceuticals on commercially commissioned field trials for MGX‑0024, according to the company’s trial disclosures. (Source: QuiverQuant reporting on field trials, FY2026.)

Smokeless Technology Corp.

Mangoceuticals acquired selected assets, executives and IP from Smokeless Technology Corp., positioning the company in the oral stimulant pouch market as part of its consumer health expansion. (Source: InvestorNews coverage, FY2025.)

NovoCare Pharmacy

NovoCare Pharmacy is identified in Mangoceuticals’ communications as a fulfillment channel used to deliver authentic Novo Nordisk medications to MangoRx/PeachesRx customers via established pharmacy pathways. (Source: GlobeNewswire clarification, November 2025; StockTwits coverage.)

LillyDirect Self‑Pay Pharmacy Solutions

LillyDirect is referenced as the fulfillment channel for Eli Lilly products made available to Mangoceuticals’ customers through the MangoRx Direct/PeachesRx Direct programs. (Source: GlobeNewswire clarification and company press, November 2025; StockTwits reporting.)

Operational constraints and what they imply for investors

Public filings and press coverage collectively show several company‑level constraints that define Mangoceuticals’ operating posture: a preference for multi‑year master agreements for core services, selective licensing deals to extend product breadth, and occasional high‑value patent purchases that materially shift balance‑sheet risk (one IP purchase is recorded at a $20 million consideration in the 10‑K). The company’s vendor spend profile is uneven: routine operational vendors sit in lower spend bands, while patent/IP transactions and planned DAT exposures represent much larger financial commitments. These are company‑level signals that indicate a high‑variance, execution‑dependent operating model rather than a steady, low‑risk supplier base.

Explore detailed supplier intelligence and risk scoring for Mangoceuticals at https://nullexposure.com/.

Bottom line for relationship management and investors

Mangoceuticals’ supplier base combines essential, long‑term service relationships (exclusive pharmacy fulfillment, physician networks) with opportunistic deals (IP purchases, digital‑asset management, animal‑health research). The core investment risk is operational concentration and execution on multiple fronts — fulfillment continuity, regulatory clarity around branded prescribing channels, and successful commercialization of acquired IP. Investors should track the exclusivity and renewal terms of pharmacy and telemedicine agreements, the progress of MGX‑0024 trials, and any clarifying statements from large pharma partners about branded product access.

If you need a vendor due‑diligence package or ongoing monitoring for MGRX supplier risk, start a review at https://nullexposure.com/.